New software for the investigation of cancer

NorayBio, a bioinformatics company located at the Bizkaia Technological Park (Basque Country) and specialising in developing software for the biosciences, has launched a new software for cancer research on to the market - BITIA, primarily aimed at research centres and cancer wards in hospitals.

BITIA aims to help oncologists to answer the question that has been around for some time: Why is it that two patients with very similar pathology profiles respond in distinct ways to treatment? It is in the genes that the answer has been looked for and recent studies have revealed that the differentiated expression of some genes is involved in the risk of developing metastasis in some kinds of cancer. The BITIA software establishes relations between genic data and clinical data of cancer patients, providing new prognostic factors. In this way, BITIA aims to be a support tool for oncologists when taking decisions.

BITIA has been designed and developed by NorayBio in collaboration with the Professor of Oncology and Palliative Medicine at the Autonomous University of Madrid and the Cancer Medical Service at the La Paz University Hospital, directed by Professor Dr. Manuel Gonzalez Barón. The involvement in this project of a multidisciplinary team of cancer specialists, molecular biologists, software engineers and statisticians has enabled the development of an easy-to-use and powerful tool for the scientific and medical community.

BITIA also optimises the commercial possibilities of NorayBio, which currently has two other software owners in the field of biopharmaceutical research: CacoReady SoftwareTM, for the study of intestinal absorption of compounds “in vitro”, and Noraymet MicrosomeTM, involved in studies “in vitro” of liver metabolism with microsomes.

http://www.basqueresearch.com/

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Targeting DUSP6 protein to prevent breast cancer recurrence